Clin2
NCT06801054Possibly a fitNot yet recruiting

Second dose of tenecteplase for stroke not responding to first

Acute Ischemic Stroke

Treatments studied

Part of Brain & nervous system, Heart & circulation clinical trials.

This trial is testing whether a second dose of a clot-busting drug called tenecteplase can help people who are having a stroke and didn't get better after the first dose. The goal is to see if the extra dose is safe and effective.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
20 people
Ages
18 years to 80 years
Study type
Interventional

Who can take part

  • You have symptoms of a stroke (like weakness, trouble speaking, or vision loss).
  • You are between 18 and 80 years old.
  • It has been less than 3 hours since your symptoms started for the first dose, and less than 4.5 hours for the second dose.
  • A CT scan shows no bleeding in the brain and a certain score (ASPECTS > 6).
  • You do not have a large vessel blockage that requires a clot removal procedure (endovascular therapy) before the second dose.
  • You are not on blood thinners (like warfarin, Xarelto, Eliquis, or Pradaxa) in the last 48 hours, or more than one antiplatelet (like aspirin and clopidogrel) in the last 48 hours.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07606807Recruiting· Phase 3
New clot-busting medication for stroke in the extended time window

This trial tests a new medication called rhTNK-tPA for treating acute ischemic stroke (a clot in the brain) up to 24 hours after symptom onset. The study uses simplified imaging to determine eligibility and aims to help patients recover better outcomes.

Guangzhou
NCT07168278Not yet recruiting· Phase 3
Tenecteplase vs standard care for large vessel stroke 4.5-24 hours

This trial tests if a clot-busting drug called tenecteplase can improve outcomes for people with a large vessel stroke when treatment starts 4.5 to 24 hours after symptoms began, and when a mechanical clot removal procedure (EVT) is not available. You would receive tenecteplase or standard medical care to see which works better.

Hefei, Anhui
NCT07092709Recruiting· Phase 3
Tenecteplase for stroke patients who recently took blood thinners

This trial tests if the clot-busting drug tenecteplase is safe and effective for people having an ischemic stroke who have recently taken blood thinners (DOACs). If you qualify, you may receive either tenecteplase or a placebo within 24 hours of your last known well time.

Guangzhou, Guangdong
NCT07621796Not yet recruiting· Phase 3
Tenecteplase for Stroke Patients Taking Blood Thinners

This trial tests whether a clot-busting drug called tenecteplase works safely in people having a stroke who are already taking certain blood-thinning medications (like apixaban or rivaroxaban). The goal is to see if it can restore blood flow to the brain better than current treatments.

Neptune City, New Jersey
NCT07475949Not yet recruiting· Phase 3
Testing a clot-busting drug for wake-up strokes without advanced scans

This trial tests if the clot-busting drug tenecteplase can help people who have a stroke with an unknown start time (like waking up with symptoms) and cannot get an advanced brain scan. It aims to see if treatment within 3 hours of noticing symptoms is safe and effective.

Nanning, Guangxi
NCT07361302Recruiting· Phase 3
Tenecteplase for stroke after 4.5 hours

This trial tests a clot-dissolving medicine called tenecteplase for people who had a stroke more than 4.5 hours ago. It may help you recover if given later than usual.

Buenos Aires

Hear when a new Acute Ischemic Stroke trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.